IQVIA Holdings, Inc., headquartered in Durham, North Carolina, is an American company focused on health information technology and clinical research. The company operates three divisions: Technology & Analytics (40% of 2024 revenues), focused on health information technology with access to 1.2 billion unique non-identified patient records globally, offers cloud-based customer relationship management application software as well as analytics consulting services all to the healthcare industry; Research & Development (55% of 2024 revenues), which is a contract research organization that handles all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, post-approval services, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics; and Contract Sales & Medical (5% of 2024 revenues), which offers contract sales to healthcare providers and patient engagement services.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | 2026-02-17 19:22:57 | 165.7 | 1.26 | 0.77 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IQV | 0001478242 | IQVIA HOLDINGS INC. | US46266C1053 | 549300W3R20NM4KQPH86 | 271341991 | NYSE | 8731 | Services-Commercial Physical & Biological Research | 1231 | DE | 2400 ELLIS ROAD | DURHAM | NC | 27703 | UNITED STATES | US | 919-998-2000 | 2400 ELLIS ROAD, DURHAM, NC, 27703 | 2400 ELLIS ROAD, DURHAM, NC, 27703 | Quintiles IMS Holdings, Inc. | Contract Research Organization | 1982 | Ari Bousbib | 88,000 | http://iqvia.com | 38,200,000,000 | 258,800,000 | 170,300,000 | IQVIA Holdings, Inc., headquartered in Durham, North Carolina, is an American company focused on health information technology and clinical research. The company operates three divisions: Technology & Analytics (40% of 2024 revenues), focused on health information technology with access to 1.2 billion unique non-identified patient records globally, offers cloud-based customer relationship management application software as well as analytics consulting services all to the healthcare industry; Research & Development (55% of 2024 revenues), which is a contract research organization that handles all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, post-approval services, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics; and Contract Sales & Medical (5% of 2024 revenues), which offers contract sales to healthcare providers and patient engagement services. | 2026-02-12 15:35:54 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 38,200,000,000 | -2,600,000,000 | -6.3725 | 176,100,000 | -5,400,000 | -2.9752 |
| 2023 | 40,800,000,000 | 600,000,000 | 1.4925 | 181,500,000 | -4,222,621 | -2.2736 |
| 2022 | 40,200,000,000 | -5,500,000,000 | -12.035 | 185,722,621 | -4,762,643 | -2.5003 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Kevin C. Knightly | President | 2018 | 517,500 | 0 | 521,475 | 575,000 | 33,351 | 2,190,182 |
| Eric M. Sherbet | Secretary, Executive Vice President, General Counsel | 2018 | 415,833 | 0 | 294,676 | 350,000 | 63,939 | 1,399,451 |
| Ari Bousbib | President, Chairman, Chief Executive Officer | 2018 | 1,600,000 | 0 | 3,911,254 | 6,300,000 | 536,516 | 16,461,779 |
| Michael R. Mcdonnell | Chief Financial Officer, President, Executive Vice President | 2018 | 650,000 | 0 | 651,772 | 600,000 | 58,560 | 2,566,555 |
| James H. Erlinger | Secretary, Executive Vice President, General Counsel | 2018 | 122,500 | 0 | 59,745 | 0 | 2,168,162 | 2,404,214 |
| Fiscal Year | Employee Count |
|---|---|
| 2019 | 67,000 |
| 2018 | 58,000 |
| 2017 | 55,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 16,310,000,000 | 15,405,000,000 | 14,984,000,000 |
| Cost Of Revenue | 10,880,000,000 | 10,030,000,000 | 9,745,000,000 |
| Gross Profit | 1,595,000,000 | 1,522,000,000 | 1,490,000,000 |
| Research And Development Expenses | — | — | — |
| General And Administrative Expenses | 1,999,000,000 | 1,992,000,000 | 2,053,000,000 |
| Operating Expenses | — | — | — |
| Operating Income | 2,182,000,000 | 2,202,000,000 | 1,977,000,000 |
| Net Income | 1,360,000,000 | 1,373,000,000 | 1,358,000,000 |
| Earnings Per Share Basic | 7.91 | 7.57 | 7.39 |
| Earnings Per Share Diluted | 7.84 | 7.49 | 7.29 |
| Weighted Average Shares Outstanding Basic | 171,900,000 | 181,300,000 | 183,800,000 |
| Weighted Average Shares Outstanding Diluted | 173,500,000 | 183,400,000 | 186,300,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 1,980,000,000 | 1,702,000,000 | 1,376,000,000 |
| Marketable Securities Current | 161,000,000 | 141,000,000 | 120,000,000 |
| Accounts Receivable | 3,400,000,000 | 3,204,000,000 | 3,381,000,000 |
| Inventories | — | — | — |
| Non Trade Receivables | 27,000,000 | 36,000,000 | 32,000,000 |
| Other Assets Current | 162,000,000 | 154,000,000 | 141,000,000 |
| Total Assets Current | 6,249,000,000 | 5,829,000,000 | 5,596,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 533,000,000 | 535,000,000 | 523,000,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 23,695,000,000 | 21,070,000,000 | 21,085,000,000 |
| Total Assets | 29,944,000,000 | 26,899,000,000 | 26,681,000,000 |
| Accounts Payable | 3,751,000,000 | 3,684,000,000 | 3,564,000,000 |
| Deferred Revenue | 2,118,000,000 | 1,779,000,000 | 1,799,000,000 |
| Short Term Debt | 1,840,000,000 | 1,145,000,000 | 718,000,000 |
| Other Liabilities Current | 489,000,000 | 193,000,000 | 294,000,000 |
| Total Liabilities Current | 8,338,000,000 | 6,957,000,000 | 6,491,000,000 |
| Long Term Debt | 13,884,000,000 | 12,838,000,000 | 12,955,000,000 |
| Other Liabilities Non Current | 688,000,000 | 668,000,000 | 698,000,000 |
| Total Liabilities Non Current | 14,976,000,000 | 13,875,000,000 | 14,078,000,000 |
| Total Liabilities | 23,314,000,000 | 20,832,000,000 | 20,569,000,000 |
| Common Stock | 11,378,000,000 | 11,143,000,000 | 11,028,000,000 |
| Retained Earnings | 7,425,000,000 | 6,065,000,000 | 4,692,000,000 |
| Accumulated Other Comprehensive Income | -943,000,000 | -1,038,000,000 | -867,000,000 |
| Total Shareholders Equity | 6,503,000,000 | 6,067,000,000 | 6,112,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,144,000,000 | 1,114,000,000 | 1,125,000,000 |
| Share Based Compensation Expense | 247,000,000 | 206,000,000 | 217,000,000 |
| Other Non Cash Income Expense | — | 0 | 0 |
| Change In Accounts Receivable | -60,000,000 | -182,000,000 | 388,000,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -96,000,000 | 115,000,000 | 267,000,000 |
| Change In Other Liabilities | 1,000,000 | 11,000,000 | 0 |
| Cash From Operating Activities | 2,654,000,000 | 2,716,000,000 | 2,149,000,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 603,000,000 | 602,000,000 | 649,000,000 |
| Acquisition Of Business | 1,714,000,000 | 735,000,000 | 876,000,000 |
| Other Investing Activities | 1,000,000 | -2,000,000 | -5,000,000 |
| Cash From Investing Activities | -2,305,000,000 | -1,444,000,000 | -1,603,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 1,323,000,000 | 1,423,000,000 | 1,052,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 1,244,000,000 | 1,350,000,000 | 992,000,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 3,400,000,000 | 960,000,000 | 2,709,000,000 |
| Other Financing Activities | -11,000,000 | — | — |
| Cash From Financing Activities | -150,000,000 | -878,000,000 | -382,000,000 |
| Change In Cash | 278,000,000 | 326,000,000 | 160,000,000 |
| Cash At End Of Period | 1,980,000,000 | 1,702,000,000 | 1,376,000,000 |
| Income Taxes Paid | — | 295,000,000 | 340,000,000 |
| Interest Paid | 647,000,000 | 589,000,000 | 556,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 7.91 | 7.57 | 7.39 |
| Price To Earnings Ratio | 28.4968 | 25.959 | 31.3099 |
| Earnings Growth Rate | 4.4914 | 2.4357 | 26.9759 |
| Price Earnings To Growth Ratio | 6.3447 | 10.6576 | 1.1607 |
| Book Value Per Share | 38.5689 | 33.4639 | 33.2535 |
| Price To Book Ratio | 5.8443 | 5.8723 | 6.9581 |
| Ebitda | 3,233,000,000 | 3,452,000,000 | 3,495,000,000 |
| Enterprise Value | 52,491,979,000 | 47,908,263,000 | 54,824,644,000 |
| Dividend Yield | 0.0341 | 0.0399 | 0.0247 |
| Dividend Payout Ratio | 0.9728 | 1.0364 | 0.7747 |
| Debt To Equity Ratio | 2.418 | 2.3048 | 2.2371 |
| Capital Expenditures | 1,142,000,000 | 1,126,000,000 | 1,116,000,000 |
| Free Cash Flow | 1,512,000,000 | 1,590,000,000 | 1,033,000,000 |
| Return On Equity | 0.2091 | 0.2263 | 0.2222 |
| One Year Beta | 1.007 | 1.1756 | 1.2317 |
| Three Year Beta | 1.096 | 1.1894 | 1.1473 |
| Five Year Beta | 1.1119 | 1.1952 | 1.1915 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Fedock Michael J. | — | 2026-02-13 | 123 | D | 9,472 |
| Haas Bernd | — | 2026-02-13 | 20 | D | 24,394 |
| DANHAKL JOHN G | Director | 2026-02-09 | 172 | A | 2,944 |
| Fasano Jim | Director | 2026-02-09 | 211 | A | 4,274 |
| GOGGINS COLLEEN A | Director | 2026-02-09 | 198 | A | 4,900 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Markwayne Mullin | Senator | 2026-01-16 | Purchase | 2025-12-29 | Joint | $15,001 - $50,000 |
| John Boozman | Senator | 2025-11-15 | Sale (Partial) | 2025-10-02 | Joint | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2025-02-27 | Purchase | 2025-02-13 | Joint | $15,001 - $50,000 |
| Markwayne Mullin | Senator | 2024-09-19 | Purchase | 2024-08-20 | Joint | $15,001 - $50,000 |
| John F Reed | Senator | 2019-03-18 | Sale (Full) | 2019-02-28 | Joint | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Rob Bresnahan | 2025-05-31 | PA08 | Sale | 2025-05-15 | — | $1,001 - $15,000 |
| Rob Bresnahan | 2025-05-08 | PA08 | Purchase | 2025-04-08 | — | $15,001 - $50,000 |
| Rob Bresnahan | 2025-03-27 | PA08 | Sale | 2025-02-25 | — | $1,001 - $15,000 |
| Susie Lee | 2023-05-26 | NV03 | Sale | 2023-05-09 | Joint | $1,001 - $15,000 |
| Daniel Goldman | 2023-05-19 | NY10 | Sale (Partial) | 2023-04-10 | — | $15,001 - $50,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| TUDOR INVESTMENT CORP ET AL | 2025-12-31 | 428,279 | 1,900 | 225.41 |
| TUDOR INVESTMENT CORP ET AL | 2025-12-31 | 9,454,822 | 41,945 | 225.41 |
| ANGELES WEALTH MANAGEMENT, LLC | 2025-12-31 | 276,353 | 1,226 | 225.4103 |
| PFM Health Sciences, LP | 2025-12-31 | 8,532,219 | 37,852 | 225.41 |
| Man Group plc | 2025-12-31 | 3,763,671 | 16,697 | 225.41 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Value Line Mid Cap Focused Fund, Inc. | 2025-12-31 | Institutional Class | VLMIX | 309,000 | 69,651,690 | 4.2208 |
| Value Line Mid Cap Focused Fund, Inc. | 2025-12-31 | VALUE LINE MID CAP FOCUSED FUND, INC. | VLIFX | 309,000 | 69,651,690 | 4.2208 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXXJX | 800,000 | 825,440 | 0.1505 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Investor Class | MXSDX | 800,000 | 825,440 | 0.1505 |
| EMPOWER FUNDS, INC. | 2025-12-31 | Institutional Class | MXKWX | 26,048 | 5,871,479.53 | 0.0635 |